According to the recent Society for Vascular Surgery practice guidelines, 1 elective repair is recommended for abdominal aortic aneurysms (AAAs) $5.5 cm in maximum diameter. Open surgical AAA repair has been used for almost 6 decades, 2 but endovascular aneurysm repair (EVAR) has emerged as a less invasive treatment alternative. Multicenter randomized trials [3] [4] [5] have demonstrated that EVAR is associated with lower 30-day mortality rates compared with open surgical repair, thus supporting the widespread use of EVAR.
The United Kingdom (UK) EVAR 1 trial recently reported its long-term results (6.0year median follow-up, interquartile range 3.9-7.3). 6 A total of 1252 patients with an AAA $5.5 cm recruited between September 1, 1999, and August 31, 2004, were randomly allocated to undergo either open surgical repair or EVAR. Twelve patients in the EVAR group and 24 patients in the open surgical repair group did not undergo AAA repair after randomization and were excluded from the analysis. As in previous reports, 3, 5 EVAR was associated with considerably lower 30-day mortality rates compared with open surgery [1.8% versus 4.3%, respectively; adjusted odds ratio 0.39, 95% confidence interval (CI) 0.18 to 0.87, p50.02]. 6 Nevertheless, this early benefit for EVAR with respect to AAA-related and overall mortality was lost by the end of the study. According to the final results, there was no difference between the 2 groups in the rate of death from any cause [adjusted hazard ratio (HR) 1.03, 95% CI 0.86 to 1.23, p50.72) or AAA-related mortality (adjusted HR 0.92, 95% CI 0.57 to 1.49, p50.73). The conclusion reached was that although EVAR was associated with a lower perioperative mortality compared with open surgical repair, there were no differences in overall total or AAArelated mortality. 6 Additionally, EVAR was associated with increased rates of graftrelated complications (12.6% versus 2.5%, respectively; adjusted HR 4.39, 95% CI 3.38 to 5.70, p,0.001) and reinterventions (5.1% versus 1.7%, respectively; adjusted HR 2.86, 95% CI 2.08 to 3.94, p,0.001) and was more costly (mean £15,303 versus £12,284, respectively; mean difference £3,019, 95% CI £1234 to £4803) compared with open surgical repair. 6 
POINTS TO CONSIDER
This editorial discusses some issues that should be entertained when interpreting the results of the UK EVAR 1 trial.
Minimum Number of EVAR Procedures
According to the UK EVAR 1 trial inclusion criteria, all participating hospitals were required to have performed a minimum of 20 EVAR procedures. 6 This number may be too small to attain proficiency and achieve optimal results. An earlier study aiming to determine the minimum number of procedures required for an interventional team to be considered well-trained in EVAR contended that 55 cases should be the minimum volume and 1 case every 10 days the minimum frequency to obtain good operative results. 7 A similar independent study found that 60 EVAR procedures (or 20 with a specific device) were required to achieve optimal outcomes. 8 Thus, the inadequate experience of some of the interventionists participating in the trial may be responsible for the increased rates of graft-related complications and reinterventions observed in the EVAR group, as well as for the 30-day (1.8%) and overall AAA-related (0.9 deaths per 100 person-years) mortality rates reported. 6 The inclusion of more experienced interventionists could have resulted in even lower 30-day (and possibly long-term AAA-related) mortality rates.
Early Recruitment Period/Older Grafts Used
Whereas open surgical AAA repair has been a well-established technique for almost 60 years, 2 EVAR was first described ,25 years ago, 9 and it was not until the mid 1990s that it began to gain popularity. At the time of patient enrollment for the UK EVAR trial (September 1, 1999, to August 31, 2004 5 ), ''older'' model endografts were mainly being used. As EVAR is constantly evolving, the performance of a similar trial today would probably yield considerably better results. Not only are newer and better devices available, but physicians also have acquired more experience; thus, the 30-day and overall AAA-related mortality, re-intervention, and complication rates could be expected to be lower than the figures reported.
Cost
Although the cost for EVAR was higher compared with open surgical repair, 6 several issues may need to be taken into consideration. The high cost as a disadvantage of EVAR has been raised in several reports. [10] [11] [12] Since there is currently an increased awareness regarding costs, it could be expected that EVAR will become more cost-effective. Furthermore, as the UK EVAR 1 authors admit, 6 an underestimation of reintervention rates and costs for the open surgical repair group may have occurred since readmission data for abdominal hernias or other complications related to open repair were not collected. Thus, not only should it be expected that EVAR will be less costly in the future, but also the total costs for the open repair group in the EVAR 1 trial were probably underestimated.
Best Medical Treatment
In the UK EVAR 1 trial, only 34.9% of the EVAR group and 36.0% of the open surgery group received a statin, while only 54.0% of the EVAR group and 51.9% of the open surgery group received aspirin preoperatively. This is in line with previous reports that AAA patients receive suboptimal best medical treatment. 13, 14 Future trials should insist on best medical treatment for AAA patients.
CONCLUSION
The recently published EVAR 1 trial demonstrated that although EVAR is associated with considerably lower 30-day mortality rates compared with open surgery, this early advantage was not associated with similar long-term benefits in total or AAA-related mortality. 6 Although the EVAR 1 trial is an excellent example of a well-designed and optimally conducted randomized trial, it suffers from some of the intrinsic flaws of such studies. Interpretation of its results should, therefore, be made with caution. The relative inexperience of some of the participating centers and the older endograft devices used may have contributed to the high reintervention and complication rates, as well as the 30day and overall AAA-related mortality rates associated with EVAR. Furthermore, it should be expected that the current cost of EVAR will be substantially less in the future. Thus, the performance of the same trial today would probably yield even better results for EVAR compared with open surgical repair for the elective treatment of AAAs. These differences may be reflected in the results of more recent randomized comparisons of EVAR and open repair for elective AAAs, such as the US Open Versus Endovascular Repair (OVER) 5 and the French Anevrysme de l'aorte abdominale, Chirurgie versus Endoprothese (ACE) 15 trials. Accordingly, final decisions regarding the role of EVAR in this setting should also consider findings from these trials, 5, 13 as well as the landmark EVAR 1 trial. 6 
